Hayat Pharmaceutical Industries Co (AMM:HPIC) EBIT : JOD3.69 Mil (TTM As of Dec. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Hayat Pharmaceutical Industries Co EBIT?

Hayat Pharmaceutical Industries Co's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2024 was JOD2.26 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2024 was JOD3.69 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Hayat Pharmaceutical Industries Co's annualized ROC % for the quarter that ended in Dec. 2024 was 28.97%. Hayat Pharmaceutical Industries Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 55.05%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Hayat Pharmaceutical Industries Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 15.99%.

Hayat Pharmaceutical Industries Co EBIT Historical Data

The historical data trend for Hayat Pharmaceutical Industries Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hayat Pharmaceutical Industries Co EBIT Chart

Hayat Pharmaceutical Industries Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT

Get a 7-Day Free Trial

4.19

4.42

4.20

2.84

3.69

Hayat Pharmaceutical Industries Co Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EBIT	Get a 7-Day Free Trial															1.69	0.40	0.70	0.32	2.26

Competitive Comparison of Hayat Pharmaceutical Industries Co's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Hayat Pharmaceutical Industries Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hayat Pharmaceutical Industries Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hayat Pharmaceutical Industries Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Hayat Pharmaceutical Industries Co's EV-to-EBIT falls into.

Save Embed

;

Save Embed

;

Hayat Pharmaceutical Industries Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was JOD3.69 Mil.

Hayat Pharmaceutical Industries Co (AMM:HPIC) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Hayat Pharmaceutical Industries Co's annualized ROC % for the quarter that ended in Dec. 2024 is calculated as:

	ROC % (Q: Dec. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2024 )	+	Invested Capital (Q: Dec. 2024 ))	/ count )
=	8.632 * ( 1 - 11.32% )	/	( (26.154	+	26.694)	/ 2 )
=	7.6548576	/	26.424
=	28.97 %

where

	Invested Capital		(Q: Sep. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	36.617	-	2.49	-	( 7.973	-	max(0, 4.75	-	23.43	+	7.973	))
=	26.154

	Invested Capital		(Q: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	37.497	-	1.758	-	( 9.045	-	max(0, 3.361	-	23.808	+	9.045	))
=	26.694

Note: The Operating Income data used here is four times the quarterly (Dec. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Hayat Pharmaceutical Industries Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2024		Q: Dec. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	9.04	/	( ( (12.982 + max(1.219, 0))	+	(13.494 + max(5.147, 0)) )	/	2 )
=	9.04	/	( ( 14.201	+	18.641 )	/	2 )
=	9.04	/	16.421
=	55.05 %

where Working Capital is:

	Working Capital		(Q: Sep. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1.049	+	4.329	+	0)	-	(2.49	+	0	+	1.669)
=	1.219

	Working Capital		(Q: Dec. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(3.119	+	3.549	+	1.305)	-	(1.758	+	0	+	1.068)
=	5.147

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Hayat Pharmaceutical Industries Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2024 )
	=	3.691	/	23.090
	=	15.99 %

Hayat Pharmaceutical Industries Co EBIT Related Terms

Thank you for viewing the detailed overview of Hayat Pharmaceutical Industries Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Hayat Pharmaceutical Industries Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hayat Pharmaceutical Industries Co (AMM:HPIC) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

Nile St. Al-Rajeeb, P.O. Box 1564, Amman, JOR, 11118

Website

https://www.hayatpharma.com

Hayat Pharmaceutical Industries Co is a Jordan based pharmaceutical manufacturing company. Its principal activity is producing human and veterinary in all its forms and medical stickers and stockings. The company is also involved in the production of medical supplies, body care lotions, cosmetics and initiating marketing campaigns as well as import and export operations. It has developed and registered hundred sixteen different dosage forms/pack sizes in the Jordan market representing fifty six different brands (molecules) in various therapeutic areas. Its products include Cardiovascular system, Infectious disease Dermatology, Gastrointestinal system, and Respiratory system.

Hayat Pharmaceutical Industries Co Headlines

No Headlines